Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
New Jersey, USA
Joined May 2009
- Tweets121K
- Following2K
- Followers50.5K
- Likes11.6K
Pinned Tweet
We’re live in Phoenix for the 2026 @sitcancer Annual Meeting!
Follow along today and all weekend for coverage of emerging data, expert interviews, and more #SITC26 #oncology
🤔 The primary efficacy end point of the KEYNOTE-866 trial evaluating perioperative pembrolizumab plus chemo cisplatin-eligible MIBC, despite surpassing other conventional benchmarks
Read more here 📰: onclive.com/view/pembrolizum…
#oncology #blcsm
WATCH: Lauren Banks, MD, PhD, of @MSKCancerCenter details the feasibility of treatment with lifileucel in metastatic or unresectable dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma @sitcancer #SITC26 #oncology onclive.com/view/dr-banks-on…
WATCH: Justin Moser, MD, of @HonorHealth details early safety and efficacy data for the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in relapsed/refractory, advanced immune-sensitive solid tumors @sitcancer #SITC26 onclive.com/view/dr-moser-on…
The addition of invikafusp alfa to sacituzumab govitecan produced preliminary antitumor activity with no new safety signals in pretreated TNBC or HR+/HER2– breast cancer in the phase 1b/2 STARt-002 trial #bcsm #oncology
Dive into the @sitcancer #SITC26 data here: onclive.com/view/invikafusp-…
Are you ready for The Five Under 5 🕘? Here is your go-to roundup of the top 5 #OncLiveTV 📹 videos of the week.
Watch the clips that made the list 🔗: hubs.li/Q04DFkLH0
An analysis from the IGNYTE trial showed RP1 plus nivolumab preserved HRQOL-adjusted survival in advanced melanoma after progression on prior anti–PD-1 therapy @sitcancer #SITC26 #melsm #oncology
Read more: onclive.com/view/rp1-plus-ni…
Steven Isakoff, MD, PhD, MMSc, of @MassGenBrigham, shares interim data for invikafusp alfa plus sacituzumab govitecan-hziy in metastatic HR+/HER2– or triple-negative breast cancer @sitcancer #SITC26 #bcsm #oncology
Watch now: onclive.com/view/dr-isakoff-…
WATCH: @LauraGrahamMD of @CUAnschutz discusses safety and efficacy data for JNJ-87189401 plus pasritamig in mCRPC @sitcancer #SITC26 #pcsm #oncology
onclive.com/view/dr-graham-o…
📰 Preliminary activity was shown for roginolisib in metastatic uveal melanoma according to data from a first-in-human phase 1 study, sending promising signals for patients and researchers
Read more here ➡️: onclive.com/view/roginolisib…
#melsm #oncology
🇪🇺 EC approval was recently granted to enfortumab vedotin plus pembrolizumab in resectable MIBC, supported by the phase 3 KEYNOTE-B15/EV-304 trial
Full details ➡️: onclive.com/view/pembrolizum…
#blcsm #oncology
Data from the phase 2 Can-Prevent-Lung trial showed canakinumab produced reductions in nodule size in a subset of patients with persistent, high-risk indeterminate pulmonary nodules @sitcancer #SITC26 #lcsm #oncology
Read more: onclive.com/view/canakinumab…
WATCH: @MatthewD_Park of @TischCancer breaks down the rationale for and outcomes of Can-Prevent-Lung @sitcancer #SITC26 #lcsm #oncology
💥 Breakthrough therapy designation! For lisaftoclax plus acalabrutinib in china for treatment-naive CLL/SLL, based on the phase 3 GLORA-2 trial
Read more here ➡️: onclive.com/view/lisaftoclax…
#oncology #leusm #lymsm
🤔 "Allowing patients to potentially avoid chemotherapy, chemoradiation, and surgery] is honestly the most exciting part right now," said Andrea Cercek, MD, of @MSKCancerCenter on the @FDA approval of dostarlimab in dMMR locally advanced rectal cancer
Full conversation 📰: onclive.com/view/fda-approva…
#oncology
We’re back for another day of interviews and intriguing presentations at @sitcancer #SITC26. Follow along for more from Arizona!
🗣️ "Ultimately, improving [TFR], responses, [and] survival will depend on how much the patient is exposed to the drug and is compliant [with] the drug," said @FadiHaddad_MD of @UTMDAnderson on TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML
Full conversation ➡️: onclive.com/view/treatment-t…
#oncology #leusm
Phase 3 data from China showed the DNA immunotherapy VGX-3100 significantly improved rates of histologic regression with concurrent HPV-16/18 clearance vs placebo in HPV-16/18–associated cervical high-grade squamous intraepithelial lesions @sitcancer #SITC26 #gynsm #oncology
Read more: onclive.com/view/vgx-3100-el…
Phase 2 translational data showed the peptide-based neoantigen vaccine EVX-01 plus pembrolizumab generated T-cell responses against patient-specific neoantigens and was associated with changes in circulating immune cell populations in advanced melanoma @sitcancer #SITC26 #melsm #Oncology
Read more: onclive.com/view/evx-01-plus…
Treatment with the allogeneic g-NK cell therapy IDP-023 plus isatuximab yielded responses in heavily pretreated R/R multiple myeloma, including in those who received prior T-cell–redirecting therapy @sitcancer #SITC26 #mmsm #oncology
Read more from a phase 1 study: onclive.com/view/idp-023-plu…
WATCH: @YanaNajjarMD of @UPMCHillmanCC discusses data for the oncolytic vaccinia virus VET3-TGI in patients with advanced solid tumors, with notable activity in cutaneous malignancies @sitcancer #SITC26 #melsm #oncology
onclive.com/view/dr-najjar-o…
